Cargando…
Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity
We investigated the influence of bronchodilating β2-agonists on the activity of human acetylcholinesterase (AChE) and usual, atypical and fluoride-resistant butyrylcholinesterase (BChE). We determined the inhibition potency of racemate and enantiomers of fenoterol as a resorcinol derivative, isoetha...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445159/ https://www.ncbi.nlm.nih.gov/pubmed/28573890 http://dx.doi.org/10.1080/14756366.2017.1326109 |
_version_ | 1783408152779161600 |
---|---|
author | Bosak, Anita Knežević, Anamarija Gazić Smilović, Ivana Šinko, Goran Kovarik, Zrinka |
author_facet | Bosak, Anita Knežević, Anamarija Gazić Smilović, Ivana Šinko, Goran Kovarik, Zrinka |
author_sort | Bosak, Anita |
collection | PubMed |
description | We investigated the influence of bronchodilating β2-agonists on the activity of human acetylcholinesterase (AChE) and usual, atypical and fluoride-resistant butyrylcholinesterase (BChE). We determined the inhibition potency of racemate and enantiomers of fenoterol as a resorcinol derivative, isoetharine and epinephrine as catechol derivatives and salbutamol and salmeterol as saligenin derivatives. All of the tested compounds reversibly inhibited cholinesterases with K(i) constants ranging from 9.4 μM to 6.4 mM and had the highest inhibition potency towards usual BChE, but generally none of the cholinesterases displayed any stereoselectivity. Kinetic and docking results revealed that the inhibition potency of the studied compounds could be related to the size of the hydroxyaminoethyl chain on the benzene ring. The additional π–π interaction of salmeterol’s benzene ring and Trp286 and hydrogen bond with His447 probably enhanced inhibition by salmeterol which was singled out as the most potent inhibitor of all the cholinesterases. |
format | Online Article Text |
id | pubmed-6445159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-64451592019-04-09 Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity Bosak, Anita Knežević, Anamarija Gazić Smilović, Ivana Šinko, Goran Kovarik, Zrinka J Enzyme Inhib Med Chem Research Paper We investigated the influence of bronchodilating β2-agonists on the activity of human acetylcholinesterase (AChE) and usual, atypical and fluoride-resistant butyrylcholinesterase (BChE). We determined the inhibition potency of racemate and enantiomers of fenoterol as a resorcinol derivative, isoetharine and epinephrine as catechol derivatives and salbutamol and salmeterol as saligenin derivatives. All of the tested compounds reversibly inhibited cholinesterases with K(i) constants ranging from 9.4 μM to 6.4 mM and had the highest inhibition potency towards usual BChE, but generally none of the cholinesterases displayed any stereoselectivity. Kinetic and docking results revealed that the inhibition potency of the studied compounds could be related to the size of the hydroxyaminoethyl chain on the benzene ring. The additional π–π interaction of salmeterol’s benzene ring and Trp286 and hydrogen bond with His447 probably enhanced inhibition by salmeterol which was singled out as the most potent inhibitor of all the cholinesterases. Taylor & Francis 2017-06-02 /pmc/articles/PMC6445159/ /pubmed/28573890 http://dx.doi.org/10.1080/14756366.2017.1326109 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Bosak, Anita Knežević, Anamarija Gazić Smilović, Ivana Šinko, Goran Kovarik, Zrinka Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity |
title | Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity |
title_full | Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity |
title_fullStr | Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity |
title_full_unstemmed | Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity |
title_short | Resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity |
title_sort | resorcinol-, catechol- and saligenin-based bronchodilating β2-agonists as inhibitors of human cholinesterase activity |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445159/ https://www.ncbi.nlm.nih.gov/pubmed/28573890 http://dx.doi.org/10.1080/14756366.2017.1326109 |
work_keys_str_mv | AT bosakanita resorcinolcatecholandsaligeninbasedbronchodilatingb2agonistsasinhibitorsofhumancholinesteraseactivity AT knezevicanamarija resorcinolcatecholandsaligeninbasedbronchodilatingb2agonistsasinhibitorsofhumancholinesteraseactivity AT gazicsmilovicivana resorcinolcatecholandsaligeninbasedbronchodilatingb2agonistsasinhibitorsofhumancholinesteraseactivity AT sinkogoran resorcinolcatecholandsaligeninbasedbronchodilatingb2agonistsasinhibitorsofhumancholinesteraseactivity AT kovarikzrinka resorcinolcatecholandsaligeninbasedbronchodilatingb2agonistsasinhibitorsofhumancholinesteraseactivity |